Compare Recursion Pharmaceuticals Inc (RXRX) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Southern Copper Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while Southern Copper Corp trades at $203.53 (market cap $176.69B). The key difference: Southern Copper Corp is far larger — about 101.5× Recursion Pharmaceuticals Inc's market cap, and Southern Copper Corp pays a 2.1% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SCCO | |
|---|---|---|
Market Cap | $1.74B | $176.69B |
Sector | Health | Basic Materials |
52-Week High | $6.79 | $219.70 |
52-Week Low | $2.84 | $102.10 |
Enterprise Value | $1.26B | $177.98B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
Southern Copper (SCCO) trades at $208.56, up 4.93% in the last 24 hours, with a bullish technical signal from moving averages and strong support near $205. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.99 exceeding expectations, and demonstrates high profitability with a net margin of 35.87% and ROE of 50.07%. Revenue growth is accelerating, reaching $13.42B in 2025, supported by rising copper prices and a $20.5B investment plan for production expansion.
The outlook for SCCO is positive due to strong copper demand from AI infrastructure and trade policy shifts, but risks include premium valuations (P/E of 31.29) and lower H1 2026 copper output. Analyst sentiment is mixed with a consensus price target of $154.58, below the current price, indicating caution despite institutional buying interest from firms like BlackRock and Bank of New York Mellon.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
